Here are four key notes:
1. Dr. Hadjipanayis has also been named director of neurosurgical oncology for New York-based Mount Sinai Health System and director of the Brain Tumor Nanotechnology Laboratory in the Tisch Cancer Institute at Mount Sinai.
2. He has a professional interest in microsurgery and radiosurgery for skull base and spinal cord tumors.
3. He was the first surgeon in the United States to perform fluorescence-guided surgery for malignant gliomas with the use of a 5-aminolevulinic acid drug called Gliolan.
4. He completed his residency in neurosurgery at the University of Pittsburgh School of Medicine, where he also earned his PhD in the department of molecular genetics and biochemistry.
More articles on spine:
Does spinal fusion union rate make a difference? 5 things to know
5 key notes on how insurance status impacts acute spinal fracture treatment
Dr. Baron Sachs launches medical billing software startup: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
